Complement factor C5a and C5a receptor contribute to morphine tolerance and withdrawal-induced hyperalgesia in rats

Experimental and Therapeutic Medicine

Volumn 4, Issue 4, 2012, Pages 723-727

  Li, Yan Hua ^a   Jin, Hua ^a   Xu, Jing Shu ^a   Guo, Guang Qiong ^a   Chen, Da Lin ^a   Bo, Yun ^a  

^a First People's Hospital of Yunnan Province   (China)

Author keywords

C5a; Hyperalgesia; Inflammation; Morphine; Tolerance

Indexed keywords

ANALGESIC AGENT; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR; MORPHINE; PMX 53; UNCLASSIFIED DRUG;

ALLODYNIA; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; CONTROLLED STUDY; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; HYPERALGESIA; LUMBAR SPINE; MALE; MORPHINE TOLERANCE; NONHUMAN; PAIN THRESHOLD; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RAT; WESTERN BLOTTING;

EID: 84865364696     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.636     Document Type: Article

References (37)

1. Raghavendra V, Rutkowski MD and DeLeo JA: The role of spinal neuroimmune activation in morphine tolerance/hyperalgesia in neuropathic and sham-operated rats. J Neurosci 22: 9980-9989, 2002.
2. Horvath RJ, Romero-Sandoval EA and De Leo JA: Inhibition of microglial P2X4 receptors attenuates morphine tolerance, Iba1, GFAP and mu opioid receptor protein expression while enhancing perivascular microglial ED2. Pain 150: 401-413, 2010.
3. Ramos KM, Lewis MT, Morgan KN, et al: Spinal upregulation of glutamate transporter GLT-1 by ceftriaxone: therapeutic efficacy in a range of experimental nervous system disorders. Neuroscience 169: 1888-1900, 2010.
4. Johnston IN, Milligan ED, Wieseler-Frank J, et al: A role for proinflammatory cytokines and fractalkine in analgesia, tolerance, and subsequent pain facilitation induced by chronic intrathecal morphine. J Neurosci 24: 7353-7365, 2004.
5. Hutchinson MR, Bland ST, Johnson KW, Rice KC, Maier SF and Watkins LR: Opioid-induced glial activation: mechanisms of activation and implications for opioid analgesia, dependence, and reward. ScientificWorldJournal 7: 98-111, 2007.
6. Woodruff TM, Ager RR, Tenner AJ, Noakes PG and Taylor SM: The role of the complement system and the activation fragment C5a in the central nervous system. Neuromolecular Med 12: 179-192, 2010.
7. Kemper C and Atkinson JP: T-cell regulation: with complements from innate immunity. Nat Rev Immunol 7: 9-18, 2007.
8. Ehrnthaller C, Ignatius A, Gebhard F and Huber-Lang M: New insights of an old defense system: structure, function, and clinical relevance of the complement system. Mol Med 17: 317-329, 2011.
9. Ricklin D, Hajishengallis G, Yang K and Lambris JD: Complement: a key system for immune surveillance and homeostasis. Nat Immunol 11: 785-797, 2010.
10. Huber-Lang MS, Riedeman NC, Sarma JV, et al: Protection of innate immunity by C5aR antagonist in septic mice. FASEB J 16: 1567-1574, 2002.
11. Recknagel S, Bindl R, Kurz J, et al: C5aR-antagonist significantly reduces the deleterious effect of a blunt chest trauma on fracture healing. J Orthop Res 30: 581-586, 2011.
12. Hecke F, Schmidt U, Kola A, Bautsch W, Klos A and Kohl J: Circulating complement proteins in multiple trauma patients-correlation with injury severity, development of sepsis, and outcome. Crit Care Med 25: 2015-2024, 1997.
13. Ganter MT, Brohi K, Cohen MJ, et al: Role of the alternative pathway in the early complement activation following major trauma. Shock 28: 29-34, 2007.
14. Gerard C: Complement C5a in the sepsis syndrome-too much of a good thing? N Engl J Med 348: 167-169, 2003.
15. Liang DY, Li X, Shi X, et al: The complement component C5a receptor mediates pain and inflammation in a postsurgical pain model. Pain 153: 366-372, 2011.
16. Jacob A, Hack B, Bai T, Brorson JR, Quigg RJ and AlexanderJJ: Inhibition of C5a receptor alleviates experimental CNS lupus. J Neuroimmunol 221: 46-52, 2010.
17. Jang JH, Liang D, Kido K, Sun Y, Clark DJ and Brennan TJ: Increased local concentration of complement C5a contributes to incisional pain in mice. J Neuroinflammation 8: 80, 2011.
18. Fonseca MI, Ager RR, Chu SH, et al: Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease. J Immunol 183: 1375-1383, 2009.
19. Yaksh TL and Rudy TA: Analgesia mediated by a direct spinal action of narcotics. Science 192: 1357-1358, 1976.
20. Stein C, Gramsch C and Herz A: Intrinsic mechanisms of antinociception in inflammation: local opioid receptors and beta-endorphin. J Neurosci 10: 1292-1298, 1990.
21. Raghavendra V, Tanga FY and DeLeo JA: Attenuation of morphine tolerance, withdrawal-induced hyperalgesia, and associated spinal inflammatory immune responses by propentofylline in rats. Neuropsychopharmacology 29: 327-334, 2004.
22. Kamei J, Ohsawa M, Hayashi SS and Nakanishi Y: Effect of chronic pain on morphine-induced respiratory depression in mice. Neuroscience 174: 224-233, 2011.
23. Song P and Zhao ZQ: The involvement of glial cells in the development of morphine tolerance. Neurosci Res 39: 281-286, 2001.
24. Hutchinson MR, Lewis SS, Coats BD, et al: Possible involvement of toll-like receptor 4/myeloid differentiation factor-2 activity of opioid inactive isomers causes spinal proinflammation and related behavioral consequences. Neuroscience 167: 880-893, 2010.
25. Rus H and Niculescu F: The complement system in central nervous system diseases. Immunol Res 24: 79-86, 2001.
26. Rus H, Cudrici C, David S and Niculescu F: The complement system in central nervous system diseases. Autoimmunity 39: 395-402, 2006.
27. Liu L, Aldskogius H and Svensson M: Ultrastructural localization of immunoglobulin G and complement C9 in the brain stem and spinal cord following peripheral nerve injury: an immunoelectron microscopic study. J Neurocytol 27: 737-748, 1998.
28. Davoust N, Jones J, Stahel PF, Ames RS and Barnum SR: Receptor for the C3a anaphylatoxin is expressed by neurons and glial cells. Glia 26: 201-211, 1999.
29. Twining CM, Sloane EM, Schoeniger DK, et al: Activation of the spinal cord complement cascade might contribute to mechanical allodynia induced by three animal models of spinal sensitization. J Pain 6: 174-183, 2005.
30. Rioux P: TP-10 (AVANT Immunotherapeutics). Curr Opin Investig Drugs 2: 364-371, 2001.
31. Shen Y and Meri S: Yin and Yang: complement activation and regulation in Alzheimer's disease. Prog Neurobiol 70: 463-472, 2003.
32. Sun T, Song WG, Fu ZJ, Liu ZH, Liu YM and Yao SL: Alleviation of neuropathic pain by intrathecal injection of antisense oligonucleotides to p65 subunit of NF-kappaB. Br J Anaesth 97: 553-558, 2006.
33. Wang Z, Ma W, Chabot JG and Quirion R: Calcitonin gene-related peptide as a regulator of neuronal CaMKII-CREB, microglial p38-NFkappaB and astroglial ERK-Stat1/3 cascades mediating the development of tolerance to morphine-induced analgesia. Pain 151: 194-205, 2010.
34. Ischenko A, Sayah S, Patte C, et al: Expression of a functional anaphylatoxin C3a receptor by astrocytes. J Neurochem 71: 2487-2496, 1998.
35. O'Barr S and Cooper NR: The C5a complement activation peptide increases IL-1beta and IL-6 release from amyloid-beta primed human monocytes: implications for Alzheimer's disease. J Neuroimmunol 109: 87-94, 2000.
36. Osaka H, McGinty A, Hoepken UE, Lu B, Gerard C and Pasinetti GM: Expression of C5a receptor in mouse brain: role in signal transduction and neurodegeneration. Neuroscience 88: 1073-1082, 1999.
37. O'Barr SA, Caguioa J, Gruol D, et al: Neuronal expression of a functional receptor for the C5a complement activation fragment. J Immunol 166: 4154-4162, 2001.